ENTERA BIO LTD. Increase Decrease Through Exercise Of Warrants Equity
ENTERA BIO LTD. (ENTX) reported Increase Decrease Through Exercise Of Warrants Equity of $12.70 million for the 3-month period ending 2021-06-30, per its 6-K filed 2021-08-16.
Discontinued › Notes
ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity · last filed 2021-08-16
- ENTERA BIO LTD. increase decrease through exercise of warrants equity for the quarter ending 2021-06-30 was $12.70M.
| Period end | Increase Decrease Through Exercise Of Warrants Equity 3 month | Increase Decrease Through Exercise Of Warrants Equity 6 month |
|---|---|---|
| 2021-06-30 | $12.70M 6-K · filed 2021-08-16 | $12.72M 6-K · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |